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Abstract: Suicide is a serious social problem in many countries, including Japan. The majority 
of people who commit suicide suffer from depression. Suicide attempt patients suffering from 
serious physical injuries are initially treated in hospital emergency departments. The present post 
hoc analysis examined data from patients admitted to an emergency hospital for treatment of 
physical injuries, resulting from a suicide attempt, and initial psychiatric treatment for depression 
and prevention of future suicide attempts. The effects on depressive symptoms were studied in 
two groups of patients using the 17-item Hamilton depression scale (HAMD). One group (n = 6) 
had received intravenous tricyclic antidepressants (TCA) (amitriptyline or clomipramine) while 
the other group (n = 7) had been treated orally with milnacipran, a serotonin and norepinephrine 
reuptake inhibitor antidepressant. Prior to treatment the four highest scoring items on the HAMD 
scale were the same in both groups namely, item 1 (depressed mood), item 3 (suicidality), item 7 
(interest in work and activities), and item 10 (psychic anxiety). After 1 week of treatment, 
mean global HAMD scores were significantly reduced in both groups. Treatment resulted in a 
significant reduction of five HAMD items in the TCA group, whereas in the milnacipran group 
12 HAMD items were significantly reduced. Suicidality (item 3) was significantly improved 
by 1 week treatment with milnacipran, but not by TCAs. Milnacipran rapidly improved a wide 
range of depressive symptoms, including suicidality within the first week. The improvement 
with milnacipran would appear to be, at least, equivalent to that achieved with TCAs, possibly 
affecting a wider range of symptoms. Since milnacipran has been shown in comparative studies 
to be better tolerated than TCAs, this antidepressant offers an interesting option for the treatment 
of suicidal patients in an emergency setting.
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Introduction
The increase in suicides has become a serious social problem in recent years in many 
countries, including Japan. The number of suicides in Japan passed 30,000 per year in 
2000 and shows no sign of decreasing.1 The number of suicide attempts is probably at 
least ten times greater than the number of completed suicides.1 It has been estimated 
that 90% of people who commit suicide suffer from psychiatric disorders2 and 70% of 
them suffer from depression. It is widely accepted that the use of psychiatric treatment 
to prevent first-time and subsequent suicide attempts is essential in order to reduce the 
number of deaths due to suicide.3–5
After a suicide attempt patients suffering from serious physical injuries, including 
traumatic injury, are usually admitted to hospital emergency departments. In addition 
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to treatment for their physical injuries, patients often receive 
acute psychiatric treatment for depression and to prevent 
future suicide attempts. There have been few studies of the 
efficacy of antidepressants in this difficult patient group. 
A recent study that reviewed long-term suicide prevention 
strategies in suicide attempters6 concluded that there is a 
need for further research to evaluate different strategies. 
A 6-month open trial in adolescents with a recent suicide 
attempt (Treatment of Adolescent Suicide Attempters 
[TASA] study) showed that intensive antidepressant and 
psychological therapy produced rates of improvement and 
remission of depression comparable to those observed 
in nonsuicidal adolescents with depression.7 The authors 
underlined the importance of events occurring within the first 
weeks after a suicide attempt and emphasized the importance 
of increased therapeutic contact early in treatment. To the 
authors’ knowledge, there has been no study on the effects 
of antidepressant treatment in patients immediately follow-
ing a suicide attempt.
The present study analyzed the records of patients admit-
ted to Juntendo Shizuoka Hospital (Japan) for treatment 
of physical injuries resulting from a suicide attempt. They 
were also administered antidepressants to treat depressive 
symptoms and to prevent suicide. The therapeutic effects of 
the antidepressants were studied in two groups of patients 
using the 17-item Hamilton depression scale (HAMD). 
One group of patients had received the classical treatment 
(in Japan at the time of the treatment) of intravenous tricyclic 
antidepressants (TCAs). The other group had been treated 
with milnacipran, a serotonin and norepinephine reuptake 
inhibitor (SNRI) antidepressant. Milnacipran is one of the 
non-TCAs most frequently prescribed in this hospital due to 
its limited adverse effects, low risk of drug interactions, and 
absence of cardiac toxicity.8
Subjects and methods
This ad hoc retrospective study analyzed data from   suicidal 
patients who were admitted to the Juntendo Shizuoka   Hospital 
(Japan) for treatment for physical injuries following a suicide 
attempt from January 2003 to March 2005. In order to be 
included in the analysis patients had to (1) have been diagnosed 
with major depressive disorder according to International 
Classification of Diseases-10 (ICD-10) criteria at hospital 
admission with an initial HAMD score of at least 26, (2) have 
been taking no psychotropic medication (including antide-
pressants) at the time of their suicide attempts, and (3) have 
full psychiatric records, including HAMD scores, for at least 
1 week following initiation of antidepressant treatment.
The patient records analyzed represented approximately 
20% of all the patients admitted to Juntendo Shizuoka 
Hospital following suicide attempts during this period.
In addition to the treatment of their injuries, each patient 
was examined by a consultant psychiatrist and the best 
antidepressant treatment, in his opinion, was prescribed. 
In choosing the treatment, the physical injuries resulting 
from the suicide attempt and their treatment, as well as 
the psychiatric condition of the patient were considered. 
Thirteen patients, treated with a TCA (n = 6) (amitriptyline 
or clomipramine) or the SNRI, milnacipran (n = 7), were 
included in this analysis (Tables 1 and 2). TCAs were initially 
administered by intravenous infusion and later switched to 
oral administration in some cases. With the exception of a 
single patient on a combination of intravenous amitriptyline 
and fluvoxamine (Table 1), the antidepressants were admin-
istered as monotherapy. No other psychotropic agents were 
prescribed.
HAMD was used to evaluate clinical symptoms of 
  depression. The first assessment was made at the time of 
  initiation of antidepressant therapy and subsequently after 
1, 2, and 4 weeks of treatment where possible. Juntendo 
  Shizuoka Hospital is an emergency hospital in a tourist region 
sadly famous for suicide attempts. Most of the patients were 
thus discharged or transferred to other hospitals, often in their 
hometown, within two weeks of admission. Therefore, it was 
only possible to observe a few patients for more than a week 
or two. For this reason HAMD ratings have only been ana-
lyzed at treatment initiation and after 1 week of treatment.
There is considerable evidence that mild depression often 
improves spontaneously even in the absence of antidepressant 
treatment, the so-called placebo effect.9 In order to reduce 
any possible bias due to the inclusion of patients with mild 
depression, only patients with baseline HAMD scores of 26 
or more were included.
Results
The clinical characteristics of the two patient groups and 
their treatment details are given in Tables 1 and 2. The mean 
initial HAMD value of the TCA group was higher than the 
milnacipran group (Table 3), although this difference was 
not quite significant (P = 0.0512). The four highest scoring 
items of the HAMD at baseline – item 1 (depressed mood), 
item 3 (suicidality), item 7 (interest in work and activities), 
and item 10 (psychic anxiety) – were the same in both groups 
(Figures 1 and 2).
In the TCA group, five of the 17 items (item 1 [depressed 
mood], item 4 [early insomnia], item 5 [middle insomnia], 
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Table 1 Clinical details of patients administered tricyclic antidepressants
No Sex Age Depression Suicide attempt details Initial 
HAMD
Treatment
Type Duration Antidepressant and doses
1 Male 58 years Unipolar 6 years Wrist cutting 40 Amitriptyline 30 mg/day iv to 50 mg/day iv. 
Transferred to another hospital after  
23 days treatment
2 Male 71 years Bipolar 28 years Self-inflicted wounds  
(electric saw) to neck  
and thigh
41 Amitriptyline 30 mg/day iv + fluvoxamine 30 mg/day   
po to 30 mg/d iv + fluvoxamine  
150 mg/day po.  
Transferred to hospital in hometown  
after 45 days treatment
3 Male 46 years Unipolar ? Drug overdose and wrist  
cutting
29 Amitriptyline 20 mg/day iv to 30 mg/day iv +  
75 mg/day po. 
Transferred to hospital in hometown  
after 9 days treatment
4 Male 54 years Unipolar ? Self-inflicted knife wound  
to the chest
48 Amitriptyline 15 mg/day iv to 50 mg/day iv. 
Left hospital after 19 days treatment
5 Male 58 years Unipolar ? Jumping in front of a train 41 Amitriptyline 15 mg/day iv to 40 mg/day iv. 
Left hospital after 109 days treatment 
for rehabilitation
6 Male 33 years Unipolar ? Drug overdose plus  
inhalation of exhaust gas
41 Clomipramine 25 mg/day iv to 50 mg/day po. 
Left hospital after 5 days treatment
Abbreviations: HAMD, 17-item Hamilton depression rating scale; iv, intravenous injection; po, oral administration.
item 6 [late insomnia], and item 10 [psychic anxiety]) 
were significantly improved after 1 week of treatment 
 ( Figure 1). In the milnacipran group, twelve of the 17 items 
(item 1 [depressed mood], item 2 [feeling of guilt], item 3 
  [suicidality], item 4 [early insomnia], item 5 [middle insom-
nia], item 6 [late insomnia], item 7 [interest in work and 
activities], item 8 [retardation], item 10 [psychic anxiety], 
item 11 [somatic anxiety], item 12 [gastrointestinal symp-
toms], and item 13 [general somatic symptoms]) were sig-
nificantly improved after 1 week of treatment (Figure 2).
As explained in the methods section, most patients were 
transferred away from the Juntendo Shizuoka Hospital after a 
week or two and only incomplete data were available beyond 
1 week’s treatment duration. In the TCA group, HAMD data 
were available after 2 weeks treatment for four patients. 
In all cases, HAMD values continued to decrease signifi-
cantly (mean 35.5 ± 4.9 at week 1 to 19.3 ± 2.5 at week 2, 
P = 0.007). The two patients for whom data were available 
after 4 weeks of treatment had HAMD values of 7 and 13.
In the milnacipran group, HAMD data were available 
after 2 weeks treatment for two patients. For both of these, 
HAMD values continued to decrease (27 to 20 and 20 to 13 
from week 1 to week 2, respectively). The single patient for 
whom data were available after 4 weeks treatment was in 
remission with a HAMD value of 3.
In the TCA group, treatment was initiated with an 
intravenous dose of 15–50 mg/day increasing within the 
first week to 30–50 mg/day (Table 1). In the milnacipran 
group, patients were rapidly titrated from the initial dose of 
30 mg/day or 50 mg/day to 50 mg/day or 100 mg/day within 
a few days (Table 2). In spite of the rapid titration, both treat-
ments were relatively well tolerated. In the TCA group, four 
of the six patients reported side effects. There was one case 
of dry mouth (sufficiently severe to cause problems of speech 
articulation), a manic switch in a bipolar patient, moderate 
drowsiness with constipation, and severe drowsiness with 
delirium. In the group of patients taking milnacipran, two 
of the seven patients reported side effects (mild drowsiness 
and palpitations). No aggravation of psychiatric symptoms 
was observed in either group. The suicidality item scored 
maximally at baseline in all patients so that no aggravation 
of suicidal tendencies could be observed on the HAMD 
score. No suicide attempts occurred during the duration of 
observation period covered by this analysis.
Discussion
All of the patients in the present analysis were initially treated 
for physical injuries resulting from their suicide attempts. 
They were all suffering from moderate to severe depression 
with strong suicidal ideation. Both antidepressant treatments 
resulted in rapid significant overall improvement in depres-
sive symptoms as determined by the mean HAMD scores at 
the end of the first week (Table 3). Treatment with TCAs 
resulted in significant reduction in the severity of depressed 
mood, the insomnia items, and psychic anxiety. The rapid 
improvement in the insomnia items is possibly related to 
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Table 3 Mean HAMD ratings in the two treatment groups before 
and after 1 week of treatment
Treatment group Initial mean  
HAMD
Mean HAMD   
after 7 days
TCA (n = 6) 40.0 ± 3.7 32.3 ± 9.0*
Milnacipran (n = 7) 34.1 ± 2.7# 16.6 ± 6.1***
Notes: #P = 0.0512 compared to the TCA group (t-test); *P = 0.042; ***P = 0.00095 
compared to the mean HAMD before treatment (paired t-test). Values are given as 
mean ± standard error of the mean. Treatment details are given in Tables 1 and 2.
Abbreviations: HAMD, 17-item Hamilton depression rating scale; TCA, tricyclic 
antidepressants.
Table 2 Clinical details of patients administered milnacipran
No Sex Age Depression Suicide attempt details Initial 
HAMD
Treatment
Type Duration Antidepressant and doses
1 Male 30 years Unipolar 6 years Drug overdose 30 Milnacipran 30 mg/day increasing to 50 mg/day  
4 days later.  
Transferred to another hospital  
after 14 days treatment
2 Male 55 years Unipolar ? Self-inflicted knife wounds  
to neck and stomach
35 Milnacipran 30 mg/day increasing to 50 mg/day  
3 days later.  
Transferred to a hospital in his  
hometown 6 days treatment
3 Male 33 years Unipolar 3 years Drug overdose and hanging 38 Milnacipran 50 mg/day increasing to 75 mg/day  
2 days later and to 100 mg/day  
8 days later.  
Discharged with outpatient  
follow up after 11 days treatment
4 Male 73 years Unipolar 4 years Pesticide poisoning and  
self-inflicted knife wounds  
to neck
33 Milnacipran 30 mg/day increasing to 50 mg/day  
5 days, to 80 mg/day 5 days later,  
and to 100 mg/day 5 days later.  
Transferred to a hospital in his  
hometown after 22 days treatment
5 Male 82 years Unipolar 6 months Self-inflicted knife wounds  
to stomach after killing his  
wife by strangulation
30 Milnacipran 30 mg/day.  
Transferred to prison hospital  
8 days later
6 Male 65 years Unipolar ? Wrist cutting as part of  
suicide pact with his wife
38 Milnacipran 50 mg/day increasing to 100 mg/day  
5 days later.  
Transferred to a hospital  
in his hometown after 15 days  
treatment
7 Female 41 years Bipolar 6 years Jumping from a stairwell  
landing
35 Milnacipran 30 mg/day increasing to 50 mg/day  
after 4 days.  
Transferred to the hospital in her 
hometown after 21 days treatment
Abbreviation: HAMD, 17-item Hamilton depression rating scale.
the well-known sedative effect of amitriptyline. Treatment 
with milnacipran had a significant effect on a wide range 
of symptoms. In addition to the symptoms improved by the 
TCAs, milnacipran also significantly improved feelings of 
guilt, suicidality, anhedonia (interest in work and activities), 
retardation, and somatic symptoms.
Of particular interest is the suicidality item. Since the 
patients had all made a very recent suicide attempt, this 
item was scored maximally (a score of four) in all patients 
at the pretreatment evaluation. After 1 week of TCA 
therapy, four out of six patients still had a score of three 
or four on this item, indicating the continued presence of 
strong suicidal   tendencies. In the milnacipran group, after 
1 week of treatment, six of the seven patients scored zero 
or one, suggesting a virtual absence of suicidal tendencies 
in most patients.
Milnacipran is not sedative8 and the significant reduction 
of the insomnia items is more likely to be part of a global 
antidepressant effect than a specific sedative effect. Such a 
global effect is also suggested by the significant improvement 
in all of the somatic symptoms.
The little data that were available at time-points beyond 
1 week suggest a continuation of the improvement seen 
during the first week.
At the time of this study, TCAs were the standard treat-
ment of depression, usually initiated by the intravenous route. 
Because of the problems of adverse effects of the TCAs, 
emergency psychiatrists have been particularly open to better 
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Figure 1 Mean scores of individual HAMD items at baseline (dark gray columns) and after 1 week of tricyclic antidepressant treatment (light gray columns). The HAMD 
items are as follows: (1) depressed mood, (2) feeling of guilt, (3) suicide, (4) early insomnia, (5) middle insomnia, (6) late insomnia, (7) work and activities, (8) retardation, (9) 
agitation, (10) psychic anxiety, (11) somatic anxiety, (12) gastrointestinal somatic symptoms, (13) general somatic symptoms, (14) genital symptoms, (15) hypochondriasis, 
(16) loss of weight, and (17) insight. 
Notes: *P , 0.05; ***P , 0.001 compared to before treatment values (paired t-test) n = 6. Treatment details are given in Table 1. 
Abbreviation: HAMD, 17-item Hamilton depression rating scale.
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Figure 2 Mean scores of individual HAMD items at baseline (dark gray columns) and after 1 week of milnacipran treatment (light gray columns). The HAMD items are as 
follows: (1) depressed mood, (2) feeling of guilt, (3) suicide, (4) early insomnia, (5) middle insomnia, (6) late insomnia, (7) work and activities, (8) retardation, (9) agitation, 
(10) psychic anxiety, (11) somatic anxiety, (12) gastrointestinal somatic symptoms, (13) general somatic symptoms, (14) genital symptoms, (15) hypochondriasis, (16) loss of 
weight, and (17) insight. 
Notes: *P , 0.05; **P , 0.01; ***P , 0.001 compared to before treatment values (paired t-test) n = 7. Treatment details are given in Table 2. 
Abbreviation: HAMD, 17-item Hamilton depression rating scale.
tolerated alternative antidepressants such as selective sero-
tonin reuptake inhibitors (SSRIs) and SNRIs. Some concerns 
have been raised that the use of SSRIs may increase the risk 
of suicide.10,11 Whether these concerns are founded or not, 
they have had the effect of dissuading psychiatrists in Japan 
from using SSRIs in overtly suicidal patients. Milnacipran has 
been shown, in comparative studies, to be equally effective 
to TCAs in treating depressive symptoms and better toler-
ated.12,13 In addition, a review of early clinical trials found that 
the risk of suicide and attempted suicide in clinical trials was 
considerably greater in patients treated with SSRIs than either 
milnacipran or TCAs.8 A recent study14 has shown that during 
treatment of depressed patients with milnacipran, suicidal 
thoughts regressed progressively in parallel with other depres-
sive symptoms. At no time was there any increase in suicidal 
thoughts even in patients who reported anxiety as an adverse 
event.14 These reassuring data have encouraged emergency 
psychiatrists to use milnacipran, the first SNRI available in 
Japan, in suicidal patients. The data from the present study 
thus have both a theoretical and practical importance.
This study has a number of weaknesses, most of them 
linked to the type of patients studied. The number of patients 
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is small and the study duration is short. In spite of these 
shortcomings, robust statistically significant effects have been 
observed. The study is a post hoc analysis of medical records. 
The limitations that this introduces, including the impossibil-
ity to make intergroup comparisons, are compensated by the 
“real-life” situation observed. Since the treatment prescribed 
was that which was considered to be “the most appropriate for 
the patient,” it is quite possible that the patients treated with 
TCAs and milnacipran differed significantly in a number of 
ways. The TCA-treated patients had more severe symptoms 
as indicated by a higher mean HAMD score at baseline, 
although this was not significant with the limited number of 
patients studied.
Finally, the absence of a placebo group leaves open the 
possibility of a “placebo effect” or spontaneous improvement. 
If this were so, however, one would have expected the results to 
be similar for the two groups, which is not the case. In addition 
the nature of records analyzed precluded the exploration of 
potential confounding factors which could have influenced the 
improvement of depressive symptoms including suicidality.
In view of these shortcomings only the most conservative 
conclusions should be drawn from this analysis. Milnacip-
ran appears to rapidly improve a wide range of depressive 
symptoms, including suicidality within the first week. The 
improvement would seem to be at least equivalent to that 
achieved with the classical treatment, TCAs, in similar 
patients and possibly affecting a wider range of symptoms. 
Since milnacipran has been shown in comparative trials to 
be better tolerated than TCAs,8 it offers an interesting option 
for the treatment of suicidal patients in an emergency setting. 
Clearly, a replication of this analysis in a larger number of 
patients is warranted.
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